An Open-label, Multi-center Study to Compare the Relative Bioavailability of Tocilizumab in Healthy Subjects Following Single Dose Subcutaneous (SC) Administration Via Disposable Auto-Injector (DAI) Device Versus Pre-filled Glass Syringe (PFS)

Trial Profile

An Open-label, Multi-center Study to Compare the Relative Bioavailability of Tocilizumab in Healthy Subjects Following Single Dose Subcutaneous (SC) Administration Via Disposable Auto-Injector (DAI) Device Versus Pre-filled Glass Syringe (PFS)

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Jun 2016

At a glance

  • Drugs Tocilizumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Pharmacokinetics
  • Sponsors Roche
  • Most Recent Events

    • 06 Jul 2012 Actual end date changed from 1 May 2012 to 1 Apr 2012 as reported by ClinicalTrials.gov record.
    • 21 May 2012 Actual patient number changed from 238 to 239 as reported by ClinicalTrials.gov.
    • 15 Feb 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top